Grabosch et al. evaluated the tumor immunogenicity and in vivo anti-tumor effect of cisplatin in two new mouse models of ovarian cancer, when used as monotherapy or combination therapy with PD-L1 inhibitors. This evidence concerns the gene CD274 and neoplasm.